Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Quote. Real-time Euronext Paris - 06/11 11:35:27 am
3.988 EUR   +2.55%
06/03NOVACYT  : Launches Two New COVID-19 Tests
MT
06/03NOVACYT  : Launch of two new PCR COVID-19 assays
PU
05/31NOVACYT  : Monthly statement on outstanding equity shares and voting rights
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt S.A. ("Novacyt", the "Company" or the “Group”): Coronavirus Update

06/02/2020 | 02:01am EDT

Sales and regulatory update

Regulatory News:

Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, provides an update on its polymerase chain reaction (PCR) test for COVID-19, developed by Primerdesign, the Company's molecular diagnostics division.

Sales

As of 1 June 2020, sales of the Primerdesign COVID-19 test are €45 million (£40 million). In addition, Primerdesign has received orders for, or been contracted to deliver, a further €90 million (£80 million) of its COVID-19 test. Therefore, currently the total sales and confirmed orders are €135 million (£120 million).

During the second half of the year, additional COVID-19 related sales are expected from the Company’s new products, Exsig™ Direct and Exsig™ Mag, and from the Company’s mobile testing solution (see further detail below).

Novacyt is now selling its COVID-19 test into more than 130 countries, with the top two countries being the UK and Germany. Novacyt is also pleased with the progress it is making in the US market and expects to update the market in due course.

Zimbabwe tender win

Following completion of a formal evaluation of the Primerdesign COVID-19 test by the Medicines Control Authority of Zimbabwe and a successful tender process, Zimbabwe’s Ministry of Health and Child Care has awarded Primerdesign with a contract for the supply of 1.5 million tests. Outside the UK, this is the largest contract secured by Novacyt to date. The initial purchase order for the first 500,000 tests has been received and will be shipped immediately. The remaining one million tests will be shipped over the coming weeks.

Regulatory – France

Following several months of discussions with the Haute Autorité de Santé (HAS), which advises the French government on medical reimbursement, the Company reports that HAS has not approved Primerdesign’s COVID-19 test for reimbursement in France. This decision by HAS is despite clinical approval from the Institut Pasteur, an internationally renowned centre for biomedical research with a goal of improving public health in France, which the Company received on 6 April 2020. HAS stated it will not authorise reimbursement because the COVID-19 test has been developed with one single gene target. Novacyt can still sell the test in France for private patient testing.

Regulatory – other territories

During the last few weeks, Novacyt has secured registrations and regulatory approvals in the following new markets for its COVID-19 test: Panama, Ecuador, Columbia, Peru, Paraguay and the UAE.

New products

As announced on 14 May 2020, the Company is working on further innovations to support laboratories during the pandemic. Exsig™ Direct is an innovative and proprietary RNA extraction reagent that removes the need for complex, automated magnetic extraction systems. Exsig™ Mag is Novacyt’s RNA extraction reagent containing magnetic beads to be used in laboratories which still wish to run their automated RNA extraction systems. The mobile COVID-19 testing solution is a combination of Exsig™ Direct and the COVID-19 test optimised to run on the Company’s proprietary q16 and q32 instrumentation. Both Exsig™ extraction reagents are on track to launch during June 2020 and the mobile COVID-19 system will launch in July 2020.

Graham Mullis, Group CEO of Novacyt, commented:

“We are encouraged by the increasing number of new markets validating our COVID-19 test for clinical use, which can be seen in the significant increase in sales and order commitments received to date. The competitive tender process and subsequent award in Zimbabwe to support the country’s national COVID-19 testing effort is a key example of our increasing global reach. As new regions are impacted by the pandemic, we expect the demand for our COVID-19 test to continue to grow.

“Despite the decision from HAS not to reimburse our COVID-19 test, we will continue to offer the test for private patient testing and evaluate new ways of supporting the French market. Our manufacturing scale-up is progressing to plan and we look forward to supporting current and additional countries with their testing requirements.”

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com


© Business Wire 2020
All news about NOVACYT
06/03NOVACYT  : Launches Two New COVID-19 Tests
MT
06/03NOVACYT  : Launch of two new PCR COVID-19 assays
PU
05/31NOVACYT  : Monthly statement on outstanding equity shares and voting rights
CO
05/26GLOBAL MARKETS LIVE : Amazon, Volkswagen, AstraZeneca, Aston Martin, Sony...
05/26NOVACYT  : Launch of VersaLab™ Portable
PU
05/26NOVACYT S.A. ("NOVACYT", THE "COMPAN : Launch of VersaLab™ Portable
BU
05/21NOVACYT  : Government and Covid test supplier Novacyt row over £150m PCR contrac..
AQ
05/21NOVACYT  : DHSC Dispute Update
PU
05/21NOVACYT S.A. ("NOVACYT", THE "COMPAN : DHSC Dispute Update
BU
05/17LONDON STOCK EXCHANGE : Banks, industrial stocks drag FTSE 100 down; Diploma jum..
RE
More news
Financials
Sales 2020 312 M 377 M 377 M
Net income 2020 185 M 224 M 224 M
Net cash 2020 102 M 123 M 123 M
P/E ratio 2020 1,52x
Yield 2020 -
Capitalization 282 M 341 M 341 M
EV / Sales 2020 0,58x
EV / Sales 2021 0,38x
Nbr of Employees 110
Free-Float 99,2%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 4,90 €
Last Close Price 3,99 €
Spread / Highest target 42,9%
Spread / Average Target 22,9%
Spread / Lowest Target 2,81%
EPS Revisions
Managers and Directors
NameTitle
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
R. A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capitalization (M$)
NOVACYT-59.31%341
MODERNA, INC.109.49%87 874
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
LONZA GROUP AG16.32%54 656